2012 Press releases


Displaying 1 - 10 of 29



10 December 2012
Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in patients with early stage acute myeloid leukaemia (AML)

Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled ...


6 December 2012
Clavis Pharma completes patient recruitment in Phase III CLAVELA study with elacytarabine in patients with acute myeloid leukaemia (AML)

Clavis Pharma ASA announces that is has reached the enrolment target for its Phase III CLAVELA ...


13 November 2012
Clavis Pharma to present at Jefferies 2012 Global Healthcare Conference in London, UK

Clavis Pharma ASA announces that the CEO, Olav Hellebø, will give a company presentation to investors at Jefferies..


12 November 2012
Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

Clavis Pharma ASA (OSE: CLAVIS) announces results of the LEAP study of CP-4126..


Clavis Pharma's Financial Calendar 2013

Clavis Pharma ASA (OSE: CLAVIS announces its Financial Calendar for 2013.


25 October 2012
Clavis Pharma - Third Quarter 2012 Results

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces today its results for the third quarter results 2012.


18 October 2012
Invitation to presentation and webcast of Clavis Pharma's third quarter results 2012

Clavis Pharma ASA (OSE: CLAVIS) presents the company's third quarter 2012 results on Thursday 25 October 2012 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway.


23 August 2012
Clavis Pharma Second Quarter and First Half 2012 Results

Clavis Pharma ASA, the Norwegian cancer drug development company, announces today its results for the second quarter and first half 2012 ...


15 August 2012
Invitation to presentation and webcast of Clavis Pharma's second quarter results 2012

Clavis Pharma ASA presents the company's second quarter 2012 results ...


8 August 2012
First patient enrolled in a clinical study with CP-4126 in combination with cisplatin in non-small cell lung cancer

Clavis Pharma ASA, the Norwegian cancer drug development company, announces that a Phase I study of ...